• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Elife . Accurate predictions of SARS-CoV-2 infectivity from comprehensive analysis

tetano

Editor, Senior Moderator
Elife


. 2024 Dec 24:13:RP99833.
doi: 10.7554/eLife.99833. Accurate predictions of SARS-CoV-2 infectivity from comprehensive analysis

Jongkeun Park[SUP] #[/SUP][SUP] 1 [/SUP], WonJong Choi[SUP] #[/SUP][SUP] 1 [/SUP], Do Young Seong[SUP] #[/SUP][SUP] 1 [/SUP], Seungpil Jeong[SUP] 1 [/SUP], Ju Young Lee[SUP] 1 [/SUP], Hyo Jeong Park[SUP] 1 [/SUP], Dae Sun Chung[SUP] 1 [/SUP], Kijong Yi[SUP] 2 [/SUP], Uijin Kim[SUP] 3 [/SUP], Ga-Yeon Yoon[SUP] 3 [/SUP], Hyeran Kim[SUP] 4 5 [/SUP], Taehoon Kim[SUP] 4 5 [/SUP], Sooyeon Ko[SUP] 6 [/SUP], Eun Jeong Min[SUP] 7 [/SUP], Hyun-Soo Cho[SUP] 3 [/SUP], Nam-Hyeok Cho[SUP] 4 5 8 [/SUP], Dongwan Hong[SUP] 1 9 10 11 12 [/SUP]



Affiliations
Abstract

An unprecedented amount of SARS-CoV-2 data has been accumulated compared with previous infectious diseases, enabling insights into its evolutionary process and more thorough analyses. This study investigates SARS-CoV-2 features as it evolved to evaluate its infectivity. We examined viral sequences and identified the polarity of amino acids in the receptor binding motif (RBM) region. We detected an increased frequency of amino acid substitutions to lysine (K) and arginine (R) in variants of concern (VOCs). As the virus evolved to Omicron, commonly occurring mutations became fixed components of the new viral sequence. Furthermore, at specific positions of VOCs, only one type of amino acid substitution and a notable absence of mutations at D467 were detected. We found that the binding affinity of SARS-CoV-2 lineages to the ACE2 receptor was impacted by amino acid substitutions. Based on our discoveries, we developed APESS, an evaluation model evaluating infectivity from biochemical and mutational properties. In silico evaluation using real-world sequences and in vitro viral entry assays validated the accuracy of APESS and our discoveries. Using Machine Learning, we predicted mutations that had the potential to become more prominent. We created AIVE, a web-based system, accessible at https://ai-ve.org to provide infectivity measurements of mutations entered by users. Ultimately, we established a clear link between specific viral properties and increased infectivity, enhancing our understanding of SARS-CoV-2 and enabling more accurate predictions of the virus.

Keywords: SARS-CoV-2; genetics; genomics; infectivity; protein prediction; viruses.

 
Back
Top